IC3 Antiplatelets Flashcards

1
Q

What are the four stages of hemostasis & thrombosis?

A
  1. vasoconstriction
  2. primary hemostasis (platelet adhesion, recruitment, aggregation)
  3. secondary hemostasis (fibrin polymerization)
  4. clot stabilization (maturation of fibrin meshwork)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which stage of hemostasis & thrombosis do antiplatelets work on?

A

primary hemostasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the general mechanism of action of antiplatelets? (Hint: Primary & secondary functions)

A

Primary
- Directly prevent platelet adhesion, activation & aggregation

Secondary
- Prevent activation of clotting factors
- Inhibit development of fibrin meshwork
(these 2^ processes are mediated by platelet adhesion/activation/aggregation; therefore, by blocking the first process, it blocks these downstream processes too)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the 4 main antiplatelet drugs we need to know?

A
  • Dipyridamole
  • Aspirin
  • Clopidogrel
  • Ticagrelor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the overarching effect of dipyridamole?

A

↑ cAMP levels –> ↑ Inhibition of platelet activation & aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the mechanisms of action of dipyridamole?

A
  1. Adenosine reuptake inhibitor
  2. PDE3 inhibitor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Explain the mechanisms of action of dipyridamole

A

Adenosine reuptake inhibitor
By inhibiting adenosine reuptake into platelets & rbc, there is a higher plasma conc of adenosine –> more adenosine available to bind to and activate A2 receptor on platelets –> ↑ cAMP levels –> ↑ Inhibition of platelet activation & aggregation

PDE3 inhibitor
PDE3 enzyme metabolizes cAMP. therefore, by inhibiting PDE3 –> ↑ cAMP levels –> ↑ Inhibition of platelet activation & aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the dose-limiting adverse effect of dipyridamole?

A

Vasodilation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Dipyridamole PK:
1. Duration of onset
2. Duration to peak activity
3. Duration of action

A
  1. Fast; 20-30min
  2. 2-2.5h
  3. Short; ~3h
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the advantage of dipyridamole due to its PK?

A

Rapid reversal is an advantage if there is concern for risk of bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the disadvantage of dipyridamole due to its PK?

A

needs to be given TDS-QDS –> hard to ensure adherence; therefore, no longer commonly used (especially since there are better agents like clopi/tica)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the side effects of dipyridamole?

A
  • headache (v common)
  • hypotension
  • dizziness
  • flushing
  • GI (N/V, diarrhoea)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What causes the side effects of dipyridamole?

A

Vasodilation effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the contraindication to dipyridamole?

A

Drug hypersensitivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What conditions should we be cautious of when prescribing dipyridamole?

A
  • hypotension
  • severe coronary artery disease
    (Induction of acute hypotension may trigger reflex tachycardia –> angina pectoris + ECG abnormalities + MI)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the drugs that displays DDI with dipyridamole?

A
  • adenosine
  • cholinesterase inhibitors (for myasthenia gravis)
  • other APs/ACs/fibrinolytics
17
Q

Describe the DDIs with dipyridamole

A

dipyridamole ↑ adenosine effects –> ↑ cardiac adenosine levels & effects

dipyridamole ↓ cholinesterase inhibitor effects –> may aggravate myasthenia gravis

risk of bleeding when combined with other APs/ACs/fibrinolytics

18
Q

What is the mechanism of action of aspirin?

A

Irreversible COX inhibitor

19
Q

Explain the mechanism of action of aspirin

A

Aspirin inhibits COX-1 in platelets –> ↓ TXA2 which PROMOTES platelet aggregation
Aspirin inhibits COX-2 in endothelial cells –> ↓ PGI2 which INHIBITS platelet aggregation

however, as aspirin is an irreversible inhibitor, it causes the irreversible inhibition of COX-1 in platelets. therefore, since platelets have no nucleus, for them to have functional COX-1 enzymes, new platelets have to be produced from megakaryocytes, which takes 7-10 days
VS
endothelial cells have nucleus, thus are able to synthesize new COX-2 in 3-4h; during this duration, low dose aspirin would have been cleared by then. therefore, newly produced COX-2 in endothelial cells will NOT be inhibited, allowing for the synthesis of PGI2

this allows for endothelial cell production of PGI2 to recover WHILE irreversible inhibition of COX-1 persists

therefore, it takes 3-4h to see clinically significant antiplatelet effect with aspirin
since not all platelets will be inhibited by aspirin, it takes 2-3 days of continuous daily administration to achieve maximal AP effects

20
Q

What is the difference when aspirin is used for antiplatelet effect and for analgesic effect?

A

antiplatelet effect requires LOW DAILY DOSE (75-100mg) OD
VS
analgesic effect requires HIGH DOSE Q4-6H

aspirin at low doses is selective for COX-1 –> allows for greater inhibition of TXA2 production > PGI2 production = overall inhibition of platelet aggregation + when given OD, it allows PGI2 production to recover while TXA2 pxn is irreversibly inhibited

aspirin at high doses inhibits both COX-1 and COX-2 –> less inhibition of platelet aggregation + when given frequently, PGI2 pxn cannot recover to establish antiplatelet effect

21
Q

What are the side effects of aspirin?

A
  • upper GI (UGI) events (eg. gastric ulcer, bleeding) (COX-1 produces protective PGs in stomach)
  • ↑ risk of bleeding & bruising
22
Q

What conditions should we be cautious of when prescribing aspirin?

A

platelet and bleeding disorders

23
Q

What DDI does aspirin have?

A

when combined with other APs/ACs/fibrinolytics –> risk of bleeding

24
Q

What drug class does clopidogrel and ticagrelor belong to?

A

ADP P2Y12 inhibitors

25
Q

Describe the mechanism of action of P2Y12i

A

Inhibition of P2Y12 receptors –> Prevents ADP released from activated platelets from binding to P2Y12 and increasing platelet expression of GPIIb/IIIa receptor –> Inhibits platelet recruitment + aggregation

26
Q

What are the side effects of clopidogrel and ticagrelor?

A
  • bleeding
  • easy bruising
  • dyspnea, bradycardia (adenosine S/E of tica)
27
Q

Describe MOA of clopidogrel

A
  • prodrug
  • active metabolite IRREVERSIBLY inhibits P2Y12 receptor
28
Q

What is the duration of action of clopidogrel?

A

7-10 days (lifetime of platelet)

29
Q

What are the contraindications of clopidogrel?

A
  • drug hypersensitivity
  • active pathologic bleeding (eg. ulcer)
30
Q

What conditions should we be cautious of when prescribing clopidogrel?

A

patients at risk of bleeding (eg. risk of intracranial hemorrhage, trauma, surgery)

31
Q

What affects clopidogrel metabolism?

A

variant alleles of CYP2C19 that is a/w reduced metabolism of clopidogrel to active metabolite (ie. reduced AP effect)

32
Q

What drugs cause an increase in AP effect (ie. increased risk of bleeding) when used with clopidogrel?

A
  • warfarin
  • NSAIDS
  • salicylates
  • rifampicin (2C19 inducer)
33
Q

What drugs cause a decrease in AP effect (ie. increased risk of clotting) when used with clopidogrel?

A
  • macrolides
  • moderate to strong 2C19 inhibitors (eg. PPI, fluoxetine, ketoconazole)
34
Q

Describe MOA of ticagrelor

A

REVERSIBLY, non-competitively binds at a diff site (not ADP binding site) to inhibit G protein activation and signalling

35
Q

What is the duration of action of ticagrelor?

A

2-3 days (shorter than clopidogrel since ticagrelor is reversible)

36
Q

What are the contraindications of ticagrelor?

A
  • drug hypersensitivity
  • SEVERE hepatic impairment (↓ CL)
  • breastfeeding
  • hx of intracranial hemorrhage in the past 6m (only cautioned for clopidogrel as it is less potent)
  • active pathologic bleeding
37
Q

What conditions should we be cautious of when prescribing ticagrelor?

A
  • patients at risk of bleeding (eg. peptic ulcer, trauma, surgery)
  • elderly
  • MODERATE hepatic impairment
38
Q

What drugs cause an increase in AP effect (ie. increased risk of bleeding) when used with ticagrelor?

A
  • ACs, fibrinolytics
  • Long-term NSAIDS
  • 3A4 inhibitors (eg. clarithromycin, ketoconazole)
  • high aspirin dose >100mg/day (NOTE: ↓ ticagrelor effects but ↑ bleeding risk)
39
Q

What drugs cause a decrease in AP effect (ie. increased risk of clotting) when used with ticagrelor?

A

3A4 inducers (eg. dexamethasone, phenytoin)